ArticleClinical rheumatology2015
Microscopic polyangiitis associated with pulmonary fibrosis.
Article in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis.Chronic respiratory diseasePooled it
- Clinical Insights and Therapeutic Strategies for the Treatment of Interstitial Lung Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Trends and Future Directions.Journal of clinical medicine · 2025Review
- Presentation and progression of MPO-ANCA interstitial lung disease.Journal of translational autoimmunity · 2024Article
- Microscopic polyangiitis presenting as idiopathic pulmonary fibrosis.Respiratory medicine case reports · 2024Article
- Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities.Annals of medicine · 2023Article
- Clinical and Prognostic Significance of p-ANCA Positivity in Idiopathic Pulmonary Fibrosis: A Retrospective Observational Study.Diagnostics (Basel, Switzerland) · 2023Article
- Microscopic polyangiitis initially presenting with idiopathic pulmonary fibrosis: a case report.Frontiers in medicine · 2023Article
- Long-term clinical course and outcomes of patients with microscopic polyangiitis-associated interstitial lung disease.Frontiers in pharmacology · 2023Article
- Uncommon onset manifestations without renal involvement in microscopic polyangiitis: A case report.Experimental and therapeutic medicine · 2022Article
- Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.Journal of clinical medicine · 2022Review
- MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectives.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Review
- Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Pulmonary Vasculitides: A Radiological Review Emphasizing Parenchymal HRCT Features.Diagnostics (Basel, Switzerland) · 2021Review
- Interstitial Lung Disease and Diffuse Alveolar Hemorrhage, the Two Key Pulmonary Manifestations in Microscopic Polyangiitis.Tuberculosis and respiratory diseases · 2021Review
- Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association.Journal of clinical medicine · 2021Article
- Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients.Clinical rheumatology · 2021Observational
- Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders.Therapeutic advances in musculoskeletal disease · 2021Review
- Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.Respirology (Carlton, Vic.) · 2021Article
- Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients.Breathe (Sheffield, England) · 2020Article
- Interstitial lung disease and microscopic polyangiitis in chilean patients.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis characterised by inflammation of the small blood vessels, the absence of granulommas on histopathological specimens, with few or no immune deposits and the presence of circulating anti-neutrophil cytoplasmic antibodies (ANCAs). The classic pulmonary manifestation is diffuse alveolar haemorrhage (DAH), but its association with pulmonary fibrosis (PF) has been increasingly reported and may be the first manifestation of MPA. Our aim was to evaluate MPA patients with PF and compare their characteristics and evolution to those of MPA patients without PF. We conducted a retrospective review of MPA patients followed in our hospital over a 15-year period. They were divided into two subgroups, with PF (MPA-PF) and without PF (MPA-non PF), and their clinical and functional features were compared. Nine of the 28 patients were classified as MPA-PF (32%). This subgroup showed significantly more respiratory symptoms and higher mortality than MPA-non PF subgroup. The most frequent chest computed tomographic pattern of PF was usual interstitial pneumonia. PF preceded other manifestations of vasculitis in five patients and occurred simultaneously in the remaining four. During the follow-up period, four deaths were reported in the MPA-PF subgroup. No deaths were registered in the MPA-non PF subgroup. We found a high prevalence of MPA-PF patients (32%), most of whom had a poor outcome and PF was often the first manifestation of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.